Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme

Neuro-Oncology

Volumn 15, Issue 5, 2013, Pages 618-625

  Rosati, Anna ^a   Poliani, Pietro Luigi ^a   Todeschini, Alice ^a   Cominelli, Manuela ^a   Medicina, Daniela ^a   Cenzato, Marco ^a   Simoncini, Edda Lucia ^a   Magrini, Stefano Maria ^a   Buglione, Michela ^a   Grisanti, Salvatore ^a   Padovani, Alessandro ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

epilepsy; glioblastoma multiforme; glutamine synthetase; immunohistochemistry; survival

Indexed keywords

BIOLOGICAL MARKER; GLUTAMATE AMMONIA LIGASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL COUNT; CLINICAL STUDY; DETERIORATION; EPILEPSY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PROTEIN EXPRESSION; SEIZURE;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; COHORT STUDIES; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DNA, NEOPLASM; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; GLUTAMATE-AMMONIA LIGASE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 84877124891     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos338     Document Type: Article

References (32)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987-996.
2. Mineo JF, Bordron A, Baroncini M, et al. Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta Neurochir. 2007; 149(3): 245-253.
3. Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008; 9(1): 29-38.
4. Vecht CJ. Neuro-oncology: clinical and molecular predictive factors. Lancet Neurol. 2009; 8(1): 17-19.
5. McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009; 110(1): 156-162.
6. Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010; 6(1): 39-51.
7. Miller PJ, Hassanein RS, Giri PG, Kimler BF, O'Boynick P, Evans RG. Univariate and multivariate statistical analysis of high-grade gliomas: the relationship of radiation dose and other prognostic factors. Int J Radiat Oncol Biol Phys. 1990; 19(2): 275-280.
8. Kilpatrick C, Kaye A, Dohrmann P, Gonzales M, Hopper J. Epilepsy and primary cerebral tumours. J Clin Neurosci. 1994; 1(3): 178-181.
9. Lote K, Stenwig AE, Skullerud K, Hirschberg H. Prevalence and prognostic significance of epilepsy in patients with gliomas. Eur J Cancer. 1998; 34(1): 98-102.
10. Ozbek N, Cakir S, Gursel B, Meydan D. Prognostic significance of seizure in patients with glioblastoma multiforme. Neurol India. 2004; 52(1): 76-78.
11. Rosati A, Marconi S, Pollo B, et al. Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels. JNeurooncol. 2009; 93: 319-324.
12. Zielke HR, Zielke CL, Ozand PT. Glutamine a major energy source for cultured mammalian cells. Fed Proc. 1984; 43: 121-125.
13. Lu W, Pelicano H, Huang P. Cancer metabolism: is glutamine sweeter than glucose? Cancer Cell. 2010; 18: 199-200.
14. Wang JB, EricksonJW, Fuji R, et al. Targetingmitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010; 18: 207-219.
15. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981; 22: 489-501.
16. Curran WJ, Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three RTOG malignant glioma trials. J Natl Cancer Inst. 1993; 85: 704-710.
17. Kleihues P, Burger PC, Aldape KD, et al. Glioblastoma. In: Louis, DN, Ohgaki, H, Wiestler, OD, Cavenee, WK, eds. WHO Classification of Tumours of the Central Nervous System. Chapter 1. Lyon, France: International Agency for Research on Cancer, 2007: 33-49.
18. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000; 343: 1350-1354.
19. Rosati A, Buttolo L, Stefini R, Todeschini A, Cenzato M, Padovani A. Efficacy and safety of levetiracetam in patients with glioma. Arch Neurol. 2010; 67: 343-346.
20. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011; 11: 85-95.
21. Osada T, Sakamoto M, Nagawa H, et al. Acquisition of glutamine synthetase expression in human hepatocarcinogenesis: relation to disease recurrence and possible regulation by ubiquitin-dependent proteolysis. Cancer. 1999; 85: 819-831.
22. Osada T, Nagashima I, Tsuno NH, Kitayama J, Nagawa H. Prognostic significance of glutamine synthetase expression in unifocal advanced hepatocellular carcinoma. J Hepatol. 2000; 33: 247-253.
23. Long J, Lang ZW, Wang HG, Wang TL, Wang BE, Liu SQ. Glutamine synthetase as a n early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas. Hepatobiliary Pancreat Dis Int. 2010; 9: 296-305.
24. Dal Bello B, Rosa L, Campanini N, et al. Glutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation. Clin Cancer Res. 2010; 16: 2157-2166.
25. Laming PR, Cosby SL, O'Neill JK. Seizures in the Mongolian gerbil are related to a deficiency in cerebral glutamine synthetase. Comp Biochem Physiol C. 1989; 94: 399-404.
26. Dutuit M, Didier-Bazes M, Vergnes M, et al. Specific alteration in the expression of glial fibrillary acid protein, glutamate deydrogenase, and glutamine synthetase in rats with genetic absence epilepsy. Glia. 2000; 32: 15-24.
27. Ortinski PI, Dong J, Mungenast A, et al. Selective induction of astrocytic gliosis generates in neuronal inhibition. Nat Neurosci. 2010; 13: 584-591.
28. Stockhammer F, Misch M, Helms HJ, et al. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure. 2012; 21: 194-7.
29. Eid T, Thomas MJ, Spencer DD, et al. Loss of glutamine synthetase in the human epileptogenic hippocampus: possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy. Lancet. 2004; 363: 28-37.
30. Berntsson SG, Malmer B, Bondy ML, Qu M, Smits A. Tumor-associated epilepsy and gliomas: Are there common genetic pathways? Acta Oncol. 2009; 48: 955-963.
31. Iliadis G, Kotoula V, Chatzisotiriou A, et al. Volumetric and MGMT parameters in glioblastoma patients: survival analysis. BMC Cancer. 2012; 12: 3.
32. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010; 35: 427-433.